Access to COVID-19 vaccines: Global approaches in a global crisis
╳
Abstract
Following the extraordinarily rapid development of COVID‑19 vaccines, immunisation is underway in many OECD countries. However, demand will continue to outstrip supply for some time and currently, distribution is strongly skewed in favour of high-income countries. This both inequitable and inefficient. Directing vaccine to where need is greatest would maximise the number of lives saved and speed bringing the pandemic under control, by slowing transmission and reducing the likelihood of the emergence of viral variants of concern. Governments should therefore act now to accelerate vaccination globally, regardless of international borders, by reallocating supplies to areas of greatest need; continuing the scaling-up of production; ensuring that necessary logistics and health care infrastructure are in place; providing further financial and in-kind support to COVAX; and developing long-term strategies tha
1st batch of Kazakhstan s homegrown vaccine QazVac released
inform.kz - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from inform.kz Daily Mail and Mail on Sunday newspapers.
Kazakhstan to apply homegrown COVID vaccine next week
aa.com.tr - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from aa.com.tr Daily Mail and Mail on Sunday newspapers.
14 April 2021 14:40 Share in:
NUR-SULTAN. KAZINFORM â The subunit vaccine against COVID-19 developed by Kazakhstani scientists is ready for clinical trials, Kazinform correspondent reports. Related news
Vice-Minister of Education and Science Miras Daulenov, several COVID-19 vaccines are being developed at the Research Institute for Biological Safety Problems, including the subunit (recombinant) vaccine, which is ready to enter clinical trials. The trials will begin after the authorization of the Health Ministry.
According to him, the Institute is also working on a polyvalent vaccine, with the British and South African variants being closely studied for updating vaccines.
Notably, the Research Institute for Biological Safety Problems is developing five COVID-19 vaccines, including the inactive QazCOVID-in vaccine, two vector vaccines, an attenuated vaccine and a subunit vaccine.